QLi5 Therapeutics GmbH, a pioneering spin-off from the Max Planck Institute for Biochemistry, has successfully raised over 6.2 million Euro in a recent capital increase. This investment, primarily led by the Korean biotech firm Qurient, alongside contributions from co-founder and Nobel laureate Prof. Dr. Robert Huber, is set to significantly bolster the development of QLi5’s innovative Proteasome Inhibitor (PI)-based Antibody-Drug Conjugate (ADC) platform.
Advancing Proteasome Inhibitor Technology
QLi5 Therapeutics is at the forefront of developing a new generation of proteasome inhibitors that utilize a groundbreaking, non-covalent mechanism of action. In collaboration with Nobel laureate Robert Huber at the Max Planck Institute, the company aims to create highly potent and selectively targeted therapies that promise enhanced pharmacokinetic properties, broader tissue distribution, and improved safety profiles.
The potential of this technology was highlighted in October 2025 when QLi5 and Qurient unveiled impressive preclinical results demonstrating the efficacy of their PI-payload-based ADCs. These innovative therapies showed remarkable anti-cancer effects in animal models that had previously resisted conventional treatments like TOP1-inhibitor-based ADCs, such as Enhertu. The findings suggested that this novel mechanism could serve as a “universal payload,” effective across various cancer cell types and models.
Capital Increase for Strategic Growth
In December 2025, QLi5 announced a capital increase totaling 6,257,600 Euro. This investment elevates Qurient’s voting stake in the company, reinforcing its commitment to advancing QLi5’s promising technology. The continued involvement of Robert Huber signals a strong endorsement of QLi5’s scientific foundation and future prospects.
The new funds are earmarked for the further development of the PI-payload technology, which represents a transformative approach intended to address the limitations of current ADC therapies. By leveraging advanced science, QLi5 aims to redefine the landscape of cancer treatment.
A Collaborative Endeavor Rooted in Science
QLi5 Therapeutics emerged from a collaborative effort involving Qurient, the Lead Discovery Center (LDC), the Max Planck Society (MPG), and Robert Huber. Huber’s groundbreaking work in structural biology led to the first elucidation of the proteasome’s three-dimensional structure, providing a solid foundation for QLi5’s innovative therapeutic strategies. This next-generation approach significantly reduces the side effects typically associated with proteasome inhibitors, expanding their applicability to a wider range of cancer types.
Kiyean Nam, CEO of Qurient, emphasized the strategic importance of this capital increase, framing it as a pivotal step to unlock the full potential of QLi5’s PI-mechanism technology. With unwavering support from Robert Huber and the robust network of LDC and MPG, QLi5 is poised to accelerate its development efforts and make meaningful contributions to the ADC market.
Support from Max Planck Innovation
The establishment of QLi5 has been supported by Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society. This support has been crucial in managing intellectual property and guiding the company through its formative stages.
Ulrich Mahr, a member of Max Planck Innovation’s general management, remarked on the significance of spin-offs like QLi5. He highlighted how they exemplify the successful translation of groundbreaking research into innovative therapeutic solutions that can significantly benefit patients. By merging exceptional scientific research with strong industrial partnerships, QLi5 embodies the essence of academic entrepreneurship in propelling forward-thinking biomedical innovation.
Dieter Link, a Senior Patenting & Licensing Manager at Max Planck Innovation, underscored the impact of Professor Huber’s research on the development of a new class of proteasome inhibitors. He noted that the recent financing will further advance this technology, facilitating the creation of differentiated therapeutic applications.
Promising Horizons in Cancer Treatment
QLi5’s advancements represent a beacon of hope in the fight against cancer and autoimmune disorders. The innovative PI-payload technology stands to not only improve existing treatments but also to create new avenues for patient care.
Takeaways:
– QLi5 Therapeutics secures over 6.2 million Euro to enhance its cancer treatment platform.
– The company focuses on a novel mechanism of action for proteasome inhibitors in ADCs.
– Ongoing collaboration with Nobel laureate Robert Huber strengthens QLi5’s scientific foundation.
– The funding aims to overcome limitations of current ADC therapies and expand their applicability.
In conclusion, QLi5 Therapeutics is not just advancing cancer treatment; it is reshaping the future of therapeutics through innovative science and strategic collaborations. As the company forges ahead, it holds the promise of delivering groundbreaking solutions that could revolutionize patient care and improve outcomes in oncology and beyond.
Read more → www.mpg.de